ArticleInternational journal of biological sciences2026
Glycolytic Reprogramming Mediated by the OTUD4-FXR1-HIF1A Axis Drives Gastric Cancer Progression.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitination and deubiquitination play critical roles in gastric cancer progression, yet systematic investigations of ubiquitin-regulating proteins in gastric cancer (GC) remain limited. To identify key regulators, we performed Ubiquitin-Focused CRISPR-Cas9 growth-based screening in GC cells and identified the deubiquitinase OTUD4 as a candidate gene promoting tumor growth. Functionally, OTUD4 was found to act as an oncogene by promoting the proliferation and metastasis of GC cell. Mechanistically, OTUD4 interacts with FXR1 through its N-terminal region (1-245 aa), and mutation of the catalytic cysteine residue (C45A) markedly impairs this interaction. OTUD4-mediated deubiquitination removes K48-linked polyubiquitin chains from FXR1, thereby protecting FXR1 from proteasomal degradation and increasing its stability. The resulting accumulation of FXR1 enhances HIF1A mRNA stability, leading to increased HIF1A expression. Consequently, HIF1A activates glycolytic programs and promotes the malignant progression of gastric cancer. Clinically, OTUD4 expression was significantly higher in tumor tissues, and higher OTUD4 levels were linked to decreased overall survival. Importantly, OTUD4 and FXR1 expression levels show a positive correlation in human GC samples. Collectively, these findings uncover an OTUD4-FXR1-HIF1A signaling axis that promotes glycolysis, which in turn functionally drives gastric cancer progression, and thereby provides a potential prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.